maravai lifesciences holdings glp-1 receptor agonist medications Comparing Ozempic, Wegovy and Other Drugs How GLP-1 medications are transforming

These findings were also found consistent across comorbidity subgroups [67]

Emerging clinical evidence, such as the STEP-HFpEF and FLOW trials, underscores the efficacy of GLP-1RAs in alleviating symptoms, improving quality of life, and slowing disease progression in HFpEF patients

Pioglitazone and bladder cancer risk: a systematic review and meta-analysis

Contract Pharma: How can the supply chain be streamlined to mitigate rising costs

Phentermine is contraindicated, and GLP-1 medications offer active cardiovascular protection

The rate of GLP-1 receptor agonist use rose more than threefold during the study period, from 8.6% in 2018 to 26.8% in 2023, the researchers found